iifl-logo-icon 1

Jenburkt Pharmaceuticals Ltd Share Price

873
(0.26%)
Jul 19, 2024|09:56:00 AM

Invest wise with Expert advice

By continuing, I accept the T&C and agree to receive communication on Whatsapp

Equities

Futures

Option

  • Open866
  • Day's High885.5
  • 52 Wk High925
  • Prev. Close870.75
  • Day's Low858.6
  • 52 Wk Low586.9
  • Turnover (lac)7.88
  • P/E14.82
  • Face Value10
  • Book Value328.41
  • EPS58.76
  • Mkt. Cap (Cr.)385.28
  • Div. Yield1.76
No Records Found

Jenburkt Pharmaceuticals Ltd KEY RATIOS

Sector

Pharmaceuticals

Open

866

Prev. Close

870.75

Turnover(Lac.)

7.88

Day's High

885.5

Day's Low

858.6

52 Week's High

925

52 Week's Low

586.9

Book Value

328.41

Face Value

10

Mkt Cap (₹ Cr.)

385.28

P/E

14.82

EPS

58.76

Divi. Yield

1.76

Jenburkt Pharmaceuticals Ltd Corporate Action

23 May 2023

12:00 AM

AGM

Announcement Date: 23 May, 2023

arrow

23 May 2023

12:00 AM

Dividend

Dividend Amount: 14.4

arrow

18 May 2024

12:00 AM

Board Meeting

Agenda : Audited Result

arrow

23 May 2023

12:00 AM

BookCloser

arrow

Jenburkt Pharmaceuticals Ltd NEWS AND UPDATE

No data found

Invest wise with Expert advice

By continuing, I accept the T&C and agree to receive communication on Whatsapp

Jenburkt Pharmaceuticals Ltd SHAREHOLDING SNAPSHOT

20 Jul, 2024|08:02 AM
  • Foreign Promoter
  • Indian Promoter
  • Institutions
  • Non Institutions
  • Custodies

Promoter- 46.70%

Foreign: 0.00%

Indian: 46.70%

Non-Promoter- 53.29%

Institutions: 0.00%

Non-Institutions: 53.29%

Custodian: 0.00%

Share Price

Jenburkt Pharmaceuticals Ltd FINANCIALS

Balance Sheet

Profit & Loss

Cash Flow

Ratios

Results

Loading...
Y/e 31 Mar( In .Cr)Mar-2024Mar-2023Mar-2022Mar-2021

Equity Capital

4.41

4.41

4.59

4.59

Preference Capital

0

0

0

0

Reserves

140.53

117.98

112.79

93.88

Net Worth

144.94

122.39

117.38

98.47

Minority Interest

View Balance Sheet
Loading...
Y/e 31 Mar( In .Cr)Mar-2022Mar-2021Mar-2020Mar-2018

Revenue

123.98

109.29

118.89

114.67

yoy growth (%)

13.43

-8.07

3.67

11

Raw materials

-31.43

-30.09

-33.06

-33.99

As % of sales

25.35

27.53

27.81

29.64

Employee costs

-36.49

-32.37

-36.51

-27.69

View Profit & Loss
Loading...
Y/e 31 Mar( In .Cr)Mar-2022Mar-2021Mar-2020Mar-2018

Profit before tax

29.87

21.64

21.13

25.26

Depreciation

-1.89

-2.03

-2.29

-1.5

Tax paid

-7.57

-5.13

-6.26

-8.05

Working capital

-4.98

-5.73

22.53

-2.1

Other operating items

View Cash Flow
Loading...
Y/e 31 MarMar-2022Mar-2021Mar-2020Mar-2018

Growth matrix (%)

Revenue growth

13.43

-8.07

3.67

11

Op profit growth

37.36

0.49

-16.99

20.62

EBIT growth

37.03

2.08

-15.64

22.94

Net profit growth

35.11

10.98

-13.61

27.42

View Ratios

No Record found

Jenburkt Pharmaceuticals Ltd Peer Comparison

Company Name
LTP
(₹)
P/E
(%)
Mkt.Cap
(₹Cr.)
NP Qtr
(₹Cr.)
Div.Yield
(%)
Sales Qtr
(₹.Cr)
Book Value
(₹)

Sun Pharmaceuticals Industries Ltd

SUNPHARMA

1,593.65

125.293,82,370.02867.60.855,536.9998.75

Divis Laboratories Ltd

DIVISLAB

4,582.3

77.221,21,645.675310.652,259507.93

Cipla Ltd

CIPLA

1,506.05

32.741,21,616.251,038.40.563,444.92346.41

Zydus Lifesciences Ltd

ZYDUSLIFE

1,185.3

34.71,19,268.911,405.20.253,172.6156.19

Dr Reddys Laboratories Ltd

DRREDDY

6,665.1

25.951,11,193.661,034.80.65,081.81,458.96

Figures of Market Capital(Mar Cap), Quarterly Net Profit(NP Qtr) and Quarterly Sales(Sales Qtr) are in ₹ Cr.

MORE ABOUT Jenburkt Pharmaceuticals Ltd

Management

Register Office

Registrar Office

Company Sec. & Compli. Officer

Ashish R Shah

Chairman & Managing Director

Ashish U Bhuta

Whole Time Director & CFO

Dilip H Bhuta

Non-Exec. & Independent Dir.

Hina Ravindra Mehta

Independent Director

Sumit Ajaybhai Thakkar

Independent Director

KRISHNAN SUBHARAMAN

Independent Director

PANKAJ .

Registered Office


Tel: -

Website: -

Email: -

Registrar Office


Tel: -

Website: -

Email: -

Summary

Jenburkt Pharmaceuticals Ltd, incorporated in 1985, was formed a venture to diversify into the healthcare and pharmaceutical industry, by Bhuta family. The Company is engaged in manufacturing and marketing of speciality and high quality pharmaceutical formulations and healthcare products.Presently, the Company manufactures and markets pharmaceutical formulations in India and internationally across 13 countries. It has more than 1,000 stockists and their reach extends to 400,000+ pharmacies across the globe. The organisation caters to government, semi-government institutions, missionary hospitals, public sector enterprises, etc. Apart from this. the Company operate manufacturing plant at Sihor-Gujarat, approved as per W.H.O (World Health Organisation) guidelines with current Good Manufacturing Practices (GMP) requirements. In addition, it has a Research & Development unit duly approved by the Ministry of Science & Technology, Government of India. Hence, the Company has strong manufacturing facilities to cater to domestic and international market.The purpose of the Company is to serve those in need of quality healthcare by bringing revolutionary, life-changing therapeutic solutions that are accessible to all. Way back in the 20th century, a visionary in the field of healthcare and philanthropic work - Shri Nandlal Mulji Bhuta laid the foundation for several groups of companies. Continuing the legacy of Shri Nandlal Mulji Bhuta, his sons Mr. Uttam N. Bhuta and Mr. Hemendra N. Bh
Read More

Company FAQs

What is the Jenburkt Pharmaceuticals Ltd share price today?

Down Arrow

The Jenburkt Pharmaceuticals Ltd shares price on BOMBAY STOCK EXCHANGE (BSE) is Rs.₹873 today.

What is the Market Cap of Jenburkt Pharmaceuticals Ltd?

Down Arrow

Market capitalization, short for market cap, is the market value of a publicly traded company's outstanding shares. The market cap of Jenburkt Pharmaceuticals Ltd is ₹385.28 Cr. as of 19 Jul ‘24

What is the PE and PB ratio of Jenburkt Pharmaceuticals Ltd?

Down Arrow

The PE and PB ratios of Jenburkt Pharmaceuticals Ltd is 14.82 and 2.65 as of 19 Jul ‘24

What is the 52 Week High and Low of Jenburkt Pharmaceuticals Ltd?

Down Arrow

The 52-week high/low is the highest and lowest price at which a Jenburkt Pharmaceuticals Ltd stock has traded during that given time period (similar to 1 year) and is considered as a technical indicator. The 52 week high and low of Jenburkt Pharmaceuticals Ltd is ₹586.9 and ₹925 as of 19 Jul ‘24

What is the CAGR of Jenburkt Pharmaceuticals Ltd?

Down Arrow

Jenburkt Pharmaceuticals Ltd's CAGR for 5 Years at 9.98%, 3 Years at 18.85%, 1 Year at 13.16%, 6 Month at 4.95%, 3 Month at 20.12% and 1 Month at 3.53%.

What is the shareholding pattern of Jenburkt Pharmaceuticals Ltd?

Down Arrow

The shareholding pattern of Jenburkt Pharmaceuticals Ltd is as follows:
Promoters - 46.71 %
Institutions - 0.00 %
Public - 53.29 %

Knowledge Centerplus
Logo

Logo IIFL Customer Care Number
(Gold/NCD/NBFC/Insurance/NPS)
1860-267-3000 / 7039-050-000

Logo IIFL Securities Support WhatsApp Number
+91 9892691696

Download The App Now

appapp
Knowledge Centerplus

Follow us on

facebooktwitterrssyoutubeinstagramlinkedin

2024, IIFL Securities Ltd. All Rights Reserved

ATTENTION INVESTORS
  • Prevent Unauthorized Transactions in your demat / trading account Update your Mobile Number/ email Id with your stock broker / Depository Participant. Receive information of your transactions directly from Exchanges on your mobile / email at the end of day and alerts on your registered mobile for all debits and other important transactions in your demat account directly from NSDL/ CDSL on the same day." - Issued in the interest of investors.
  • KYC is one time exercise while dealing in securities markets - once KYC is done through a SEBI registered intermediary (broker, DP, Mutual Fund etc.), you need not undergo the same process again when you approach another intermediary.
  • No need to issue cheques by investors while subscribing to IPO. Just write the bank account number and sign in the application form to authorise your bank to make payment in case of allotment. No worries for refund as the money remains in investor's account."

www.indiainfoline.com is part of the IIFL Group, a leading financial services player and a diversified NBFC. The site provides comprehensive and real time information on Indian corporates, sectors, financial markets and economy. On the site we feature industry and political leaders, entrepreneurs, and trend setters. The research, personal finance and market tutorial sections are widely followed by students, academia, corporates and investors among others.

RISK DISCLOSURE ON DERIVATIVES
  • 9 out of 10 individual traders in equity Futures and Options Segment, incurred net losses.
  • On an average, loss makers registered net trading loss close to Rs. 50,000.
  • Over and above the net trading losses incurred, loss makers expended an additional 28% of net trading losses as transaction costs.
  • Those making net trading profits, incurred between 15% to 50% of such profits as transaction cost.
Copyright © IIFL Securities Ltd. All rights Reserved.

Stock Broker SEBI Regn. No: INZ000164132, PMS SEBI Regn. No: INP000002213,IA SEBI Regn. No: INA000000623, SEBI RA Regn. No: INH000000248

plus
We are ISO 27001:2013 Certified.

This Certificate Demonstrates That IIFL As An Organization Has Defined And Put In Place Best-Practice Information Security Processes.